Pipeline – Mobocertinib

Overview¹

Mobocertinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) that can be administered daily

Mechanism of Action¹

- Mobocertinib irreversibly binds to and inhibits EGFR exon 20 insertion mutations at lower concentrations than wild type EGFR

Clinical Trials

Study Name

A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Study Name

A Phase 1/2 Study of the Oral EGFR/HER2 Inhibitor TAK-788 in Japanese Non-Small Cell Lung Cancer Patients

Study Name

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in Non-Small Cell Lung Cancer

References

1. Exkivity^® [package insert]. Takeda Pharmaceuticals America, Inc.